Back to results
US 2016/0096805 A1Published application
Kinase inhibitor
AssigneesRespivert Limited, Topivert Pharma Limited
InventorMatthew Colin Thor FYFE
Life of this patent
Estimating the term…
Abstract
There is provided a compound of formula I, which compound has antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and has use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
Claims15
A compound of formula I,
- or a pharmaceutically acceptable salt thereof.
A process for the preparation of a compound of formula I, which process comprises:
- (a) reaction of a compound of formula II,
- with a compound of formula III,
- wherein one of Z1 and Z2 is a structural fragment of formula IV
- and the other of Z1 and Z2 is a structural fragment of formula V
- (b) reaction of a compound of formula IIa,
- wherein Z1 is as defined above, with a suitable azide-forming agent,
- which reaction is followed, without isolation, by thermal rearrangement of the intermediate acyl azide (of formula Z1—C(O)—N3) to provide, in situ, a compound of formula II, which compound is then reacted with a compound of formula III as defined above;
- (c) reaction of a compound of formula IIb,
- wherein LG1 represents a leaving group and Z1 is as defined above, with a compound of formula III, as defined above;
- (d) reaction of a compound of formula VI,
- wherein LG2 represents a leaving group, with a compound of formula VII,
- or
- (e) deprotection of a protected derivative of the compound of formula I, wherein the protected derivative bears a protecting group on an O- or N-atom of the compound of formula I.
10 more elements
Dependencies are inferred from the claim text.